

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-154: (Cancelled).

Claim 155 (previously presented): An isolated antigen-binding fragment comprising a polypeptide domain that specifically binds a BDCA-2 protein encoded by SEQ ID NO:1; wherein said BDCA-2 protein is encoded by exons 1-6; exons 1 and 3-6; exons 1-2 and 4-6; or exons 1-3 and 5-6 of SEQ ID NO:1.

Claim 156 (previously presented): The antigen-binding fragment of claim 155 that is a monoclonal antibody comprising two heavy and two light chains.

Claim 157 (previously presented): The antigen-binding fragment of claim 156 where the antibody is human, murine, humanized or a bispecific antibody.

Claim 158 (previously presented): The antigen-binding fragment of claim 155 that is a Fab, F(ab')₂, scFv, or fusion polypeptide, or is encoded by a phage display library.

Claim 159 (previously presented): The antigen-binding fragment of claim 155 wherein the BDCA-2 protein is glycosylated.

Claim 160 (cancelled)

Claim 161 (previously presented): The antigen-binding fragment of any of claims 155-159 that is conjugated to a chemically functional moiety.

Claim 162 (previously presented): The antigen-binding fragment of claim 161 wherein the chemically functional moiety is selected from the group consisting of a radioisotope, fluorescent compound, chemiluminescent compound, bioluminescent compound, enzyme, and a paramagnetic label.

Claim 163 (previously presented): The antigen-binding fragment of any of claims 155-159 that is bound to a BDCA-2 protein.

Claim 164 (previously presented): The antigen-binding fragment of any of claims 155-159 that is bound to a cell that expresses a BDCA-2 protein.

Claim 165 (previously presented): The antigen-binding fragment of claim 164 wherein the cell is a dendritic cell.

Claim 166 (previously presented): The antigen-binding fragment of claim 165 wherein the dendritic cell is BDCA-4⁺.

Claim 167 (previously presented): The antigen-binding fragment of claim 166 wherein the dendritic cell is human.

Claim 168 (withdrawn): The antigen-binding fragment of claim 165 wherein an anti-BDCA-4 antibody is also bound to the dendritic cell.

Claim 169 (previously presented): A composition comprising the antigen-binding fragment of claim 155 composition and a pharmaceutically acceptable excipient.

Claim 170 (previously presented): An isolated cell that produces an antigen-binding fragment of claim 155.

Claim 171 (previously presented): A hybridoma that produces an antigen-binding fragment of claim 156.

Claim 172 (previously presented): A method for preparing a population of cells enriched for BDCA-2⁺ cells, comprising contacting a mixture of human cells with an antigen-binding fragment of claim 155 and isolating cells to which the antigen-binding fragment binds.

Claim 173 (currently amended): A method of detecting BDCA-2 protein in a biological sample comprising (a) contacting the BDCA-2 protein with the antigen-binding fragment

thereof of claim 155 under conditions that permit formation of a complex between the BDCA-2 protein and the antigen-binding fragment ; and (b) detecting the formation of the complex.

Claim 174 (previously presented): The method of claim 173 wherein the BDCA-2 protein is displayed on the surface of a dendritic cell.

Claim 175 (previously presented): The method of claim 174 wherein the step of detecting the formation of the complex comprises detecting at least one metabolic change in the dendritic cell.

Claim 176 (previously presented): The method of claim 175 wherein the metabolic change is down-regulation of type I interferon production, down-regulation of Th1 immune responses, induction of intracellular Ca^{2+} mobilization, or polarization of an immune response to Th2.

Claim 177 (previously presented): A method of ligating BDCA-2 antigen on a dendritic cell comprising contacting the cell with the antigen-binding fragment of claim 155.

Claim 178 (currently amended): A method of screening for pharmaceutically effective agents that interfere with ligation of BDCA-2, said method comprising contacting a BDCA-2 protein substantially pure population or subpopulation of dendritic cells and an antigen-binding fragment claim 155 in the presence of a test agent ~~and determining whether the test agent reduces binding of the antigen-binding fragment to the protein~~; monitoring the response of the cells to the agent; comparing the response of the cells to the agent to cells exposed to a control agent; and determining whether the test agent modulated any one immunologic properties of the isolated cell.

Claim 179 (previously presented): A kit comprising an antigen-binding fragment of claim 155 and a at least one component selected from the group consisting of: a buffer, a label, a label conjugated to the antigen-binding fragment, and a reagent capable of combining with the antigen binding-fragment.

Claim 180 (new): The method of claim 173, wherein at least 80% of the cells in the population of cells enriched for BDCA-2⁺ cells are BDCA-2⁺ cells.